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ABSTRACT 
Purpose. Systematic review comparing biological agents, targeting tumour necrosis 
factor , for sciatica with placebo and alternative interventions. 
Methods. We searched 21 electronic databases and bibliographies of included studies. 
We included randomised controlled trials (RCTs), non-RCTs and controlled 
observational studies of adults who had sciatica treated by biological agents compared 
with placebo or alternative interventions. 
Results. We pooled the results of six studies (five RCTs and one non-RCT) in meta-
analyses. Compared with placebo biological agents had: better global effects in the 
short term odds ratio (OR) 2.0 (95% CI 0.7 to 6.0), medium term OR 2.7 (95% CI 1.0 to 
7.1) and long term OR 2.3 [95% CI 0.5 to 9.7); improved leg pain intensity in the short 
term weighted mean difference (WMD) -13.6 (95% CI -26.8 to -0.4), medium term WMD 
-7.0 (95% CI -15.4 to 1.5), but not long term WMD 0.2 (95% CI -20.3 to 20.8); improved 
Oswestry Disability Index (ODI) in the short term WMD -5.2 (95% CI -14.1 to 3.7), 
medium term WMD -8.2 (95% CI -14.4 to -2.0), and long term WMD -5.0 (95% CI -11.8 
to 1.8). There was heterogeneity in the leg pain intensity and ODI results and 
improvements were no longer statistically significant when studies were restricted to 
RCTs. There was a reduction in the need for discectomy, which was not statistically 
significant, and no difference in the number of adverse effects.  
Conclusions. There was insufficient evidence to change practice, but sufficient 
evidence to suggest that larger RCTs are needed. 
Key words: sciatica, systematic review, meta-analysis, biological agents, tumour 
necrosis factor  
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INTRODUCTION 
Sciatica is a symptom defined as unilateral, well-localised leg pain, with a sharp, 
shooting or burning quality, that approximates to the dermatomal distribution of the 
sciatic nerve down the posterior lateral aspect of the leg, and normally radiates to the 
foot or ankle. It is often associated with numbness or paraesthesia in the same 
distribution [1]. Sciatica caused by lumbar nerve root pain usually arises from a 
prolapsed intervertebral disc [2], not only from compression of the nerve root [3], but 
also the release of pro-inflammatory factors from the damaged disc [4]. Sciatica is 
common [5], disabling [6-8] and costly to society [9]. Between 5-15% of patients with 
sciatica are treated with surgery [6,8], usually involving a lumbar discectomy. In the NHS 
in England in 2010/11 11,765 lumbar discectomies were performed [10].  
 
Pro-inflammatory factors released from the prolapsed intervertebral disc include: 
phospholipase A2, prostaglandin E2, interleukin-1 (IL-1), IL-1, IL-6, nitric oxide and 
tumour necrosis factor  (TNF). It has been suggested that TNF is the cytokine of 
primary importance in the pathophysiology of sciatica [4]. Biological treatments targeting 
TNF (etanercept, infliximab, adalimumab) are increasingly used in rheumatological 
practice to control inflammatory disease, and may be useful in sciatica [11]. A 
systematic review was conducted to ascertain the effectiveness of biological agents 
targeting TNF for the treatment of sciatica, or lumbar nerve root pain, compared with 
placebo or alternative interventions. Outcomes included global effects, pain intensity, 
condition-specific outcome measures, adverse effects, work status and disc surgery 
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rates. Non-randomised and randomised controlled trials as well as controlled 
observational studies were included. 
 
METHOD 
This review used updated searches from a larger review evaluating the effectiveness 
and cost-effectiveness of all treatment strategies for sciatica [12], and was prepared in 
accordance with the PRISMA guidelines [13]. 
 
Literature search 
The following databases were searched (from inception to February 2012) using 
strategies designed for each database: MEDLINE, EMBASE, CINAHL, AMED, British 
Nursing Index, Health Management Information Consortium, PsychINFO, Inspec, 
Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews of 
Effects, Cochrane Database of Systematic Reviews, Health Technology Assessment 
database, NHS Economic Evaluation database, System for Information on Grey 
Literature, Science Citation Index, Social Science Citation Index, Index to Scientific and 
Technical proceedings, PEDro, BIOSIS, National Research Register, and other trial 
registries (n=7) available via the internet. An example of the search strategy for 
MEDLINE is presented in an appendix. No language restriction was used. The 
bibliographies of previous systematic reviews and included studies were screened to 
identify further relevant studies.  
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Included studies 
The following study designs were included: randomised controlled trials (RCTs), non-
RCTs and cohort studies with concurrent or historical controls. Studies with adults who 
had sciatica or lumbar nerve root pain diagnosed clinically or confirmed by imaging were 
eligible. Any biological agent targeting pro-inflammatory factors such as tumour necrosis 
factor- compared with placebo or alternative interventions using any relevant patient 
based outcome measure were included. 
 
Data extraction  
Two reviewers independently screened the titles and abstracts for relevance. Full 
papers of potentially relevant studies were retrieved and assessed for inclusion, using 
the criteria reported above, by two independent reviewers. Data were extracted using 
predefined forms on a Microsoft Access database by one reviewer and checked for 
accuracy, against the original paper, by a second independent reviewer. Any 
disagreements were resolved by discussion or by a third reviewer if necessary.  
 
Quality assessment 
Quality assessment was undertaken by two independent reviewers with differences 
being resolved by consensus or by a third reviewer if necessary. We adapted a quality 
checklist [14,15] to be suitable for both RCTs and controlled observational studies of 
sciatica containing the criteria: external validity, selection bias and confounding, 
detection bias, performance bias, and attrition bias (Table 3).  
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Data analysis/synthesis 
Pairwise meta-analyses were conducted for dichotomous and continuous outcomes. 
Continuous data were synthesised using final mean scores as weighted mean 
differences. Where mean values were unavailable but the medians were reported, these 
were used instead. Missing standard deviations (SDs) were derived using methods 
reported in the Cochrane Handbook [16], substituted with baseline values, or imputed 
using the weighted mean for each intervention category [17]. Studies were pooled using 
the random effects model [18] in Revman version 5; with between study heterogeneity 
examined using I2 and Chi2 statistics. Sensitivity analyses assessed the effect of 
substituting mean values with medians, using imputed SDs and excluding non-
randomised studies.  
 
RESULTS 
The electronic searches identified 38443 references and a further 33 references were 
identified by hand searching, 954 papers were retrieved in full, 435 studies of sciatica 
were identified, nine of which evaluated biological agents (Figure 1).  
 
Description of biological agents studies 
We identified seven RCTs [19-26] one non-RCT [27,28] and one historical cohort study 
[29]. Two studies were reported in two separate publications each [23,24,27,28]. One 
non-RCT [27,28] and two RCTs [22-24] compared intravenous infusions of infliximab 
with placebo injections of saline. One RCT compared subcutaneous injection of 
etanercept with a placebo injection of saline [25], and another RCT compared three 
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different doses of an epidural injection of etanercept with each other and with an 
epidural saline injection [20]. One three-armed RCT compared epidural injections of 
etanercept with epidural injections of corticosteroid and with epidural injection of saline 
[26]. One RCT compared subcutaneous injections of adalimumab with placebo 
injections [21] (Table 1). One RCT compared epidural injections of autologous 
conditioned serum, rich in anti-inflammatory cytokines, compared with epidural injections 
of corticosteroid and local anaesthetic [19]. One historical cohort study compared sub-
cutaneous injections of etanercept with intra-venous injections of corticosteroid [29] 
(Table 2).  
 
The nine studies included 412 participants with mean ages between 39 and 54 years, 
with 40-80% men, five with acute [21-24,27-29], one with chronic [25] and three with 
acute and chronic symptom duration [19,20,26] (Tables 1 and 2). Three RCTs included 
patients with recurrent symptoms [21,23,24,29], but symptom recurrence was not 
reported in six studies [19,20,22,25,26,29]. Sciatica was confirmed by imaging in all 
studies and previous back surgery was excluded in five trials [22-28]. 
 
Most of the studies were RCTs (7/9 78%) and one was good quality [21]. Five reported 
an adequate method of random number generation [19,21-24], but only three 
documented a secure method of allocation concealment [21,25,26]. Three studies had 
moderately good external validity [21,26,29] (Table 3). Two RCTs reported medians 
rather than means [22-24]. Three RCTs did not report SDs [22-25], but were provided by 
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the authors in one RCT [25]. Imputed SDs were used in the meta-analyses for the 
remaining missing values [22-24].  
 
Biological agent versus placebo 
Global effect  
Five studies reported a measure of global improvement (Table1). One poor quality non-
RCT [27,28], two moderate quality [20,26] and one good quality RCT [21] were 
combined in meta-analyses at short term (4 to 6 weeks) and medium term (6 months) 
follow-up. One poor quality non-RCT [27,28] and one moderate quality RCT [23,24] 
were combined in a meta-analysis at long-term (12 months) follow-up. Combined odds 
ratios (ORs) were in favour of biological agents at all three time periods, but were only 
statistically significant at medium term follow-up. Indeed there was moderate 
heterogeneity at short (I2=62%), medium (I2=47%) and long term (I2=47%) follow-up. 
ORs were 1.99 (95% CI 0.66 to 5.96) in the short term, 2.72 (95% CI 1.04 to 7.13) in the 
medium term and 2.26 (95% CI 0.53 to 9.73) in the long term (Figure 2). A sensitivity 
analysis excluding the non-RCT [27,28] only resulted in minimal changes to the 
summary OR and measurements of heterogeneity. 
 
Leg pain intensity 
Seven studies reported leg pain intensity measured with a visual analogue scale. One 
poor quality non-RCT [27,28], five moderate quality [20,22-25] and one good quality 
RCT [21] were combined in a meta-analysis at short term (4 to 6 weeks) follow-up and 
found a moderate weighted mean difference (WMD) of -13.63 units on a 0-100 visual 
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analogue scale (95% CI -26.84 to -0.41)  in favour of biological agents. Five of these 
studies were combined in a meta-analysis at medium term (3 to 6 months) follow-up [21-
25,27,28] and found a small WMD of -6.96 (95% CI -15.42 to 1.51) in favour of biological 
agents. One poor quality non-RCT [27,28] and one moderate quality RCT [23,24] were 
combined in a meta-analysis at long-term (12 months) follow-up and found no difference 
with a WMD of 0.18 (95% CI -20.39 to 20.75) (Figure 3). There was substantial 
heterogeneity at short (I2=69%) and long term (I2=86%), but not medium term, follow-up. 
A sensitivity analysis excluding the non-RCT [19,27] reduced the size of the WMDs and 
heterogeneity, so that the WMD at short term follow-up was no longer statistically 
significant. Excluding the two RCTs reporting medians [22-24] or the two RCTs with 
imputed SDs [22-24] had minimal effect at short and medium term follow-up. A funnel 
plot for publication bias did not appear to show asymmetry, but indicated a lack of large 
studies. 
 
Oswestry Disability Index 
Seven studies reported the Oswestry Disability Index. One poor quality non-RCT 
[27,28], four moderate quality [20,22-25] and one good quality RCT [21] were combined 
in a meta-analysis at short term (4 to 6 weeks) follow-up and found a WMD of -5.21 
units (95% CI -14.09 to 3.68) on the ODI (range 0-100) in favour of biological agents. 
Five of these studies were combined in a meta-analysis at medium term (3 to 6 months) 
follow-up [21-25,27,28] and found a WMD of -8.16 (95% CI -14.36 to -1.96) in favour of 
biological agents. One poor quality non-RCT [27,28] and one moderate quality RCT 
[23,24] were combined in a meta-analysis at long-term (12 months) follow-up and found 
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a WMD of -4.99 (95% CI -11.78 to 1.80) in favour of biological agents (Figure 4). There 
was moderate heterogeneity at short (I2=77%), medium (I2=45%) and long term 
(I2=61%) follow-up. A sensitivity analysis excluding the non-RCT [27,28] reduced the 
size of the WMDs so that the WMD at medium term follow-up was no longer statistically 
significant. Excluding the two RCTs reporting medians, for which we also imputed SDs 
[22-24], had minimal effect at short and medium term follow-up but increased the WMD 
at long term follow-up because only one non-RCT remained with a larger effect size 
[27,28]. The funnel plot for publication bias did not appear to show asymmetry, but 
indicated a lack of large studies. 
 
Biological agent versus corticosteroid injection 
Only three studies compared biological agents with an alternative treatment. One 
moderate quality RCT [19] compared epidural injection of autologous conditioned serum 
with epidural corticosteroid injection and found no statistically significant difference in 
mean overall pain intensity or mean ODI at short or medium term follow-up. One 
moderate quality RCT [26] compared epidural injection of etanercept with epidural 
corticosteroid injection and found no statistically significant difference in mean pain 
intensity, but a statistically significant improvement in ODI and global effects in favour of 
corticosteroid, in the short term (Figures 5 and 6). One poor quality historical cohort 
study [29] compared sub-cutaneous injections of etanercept with intra-venous injections 
of corticosteroid and found a statistically significant difference in global effects, mean leg 
pain intensity and ODI at short term follow-up (Figures 5-7).  
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Need for disc surgery  
One poor quality non-RCT [27,28], three moderate quality [22-25] and one good quality 
RCT [21] were combined in a meta-analysis of the need for disc surgery. The combined 
odds ratio for needing disc surgery in those receiving biological agents compared with 
placebo was 0.54 (95% CI 0.26 to 1.14) with homogeneity amongst the effect sizes (I2 
=0%) (Figure 8). In addition, a poor quality cohort study [29] reported that one patient 
(10%) in the etanercept group and one (10%) in the intravenous corticosteroid group 
required disc surgery.  
 
Employment outcomes 
In one moderate quality RCT [23,24] there was a median of 42 days sick leave in the 
infliximab group compared with 25 days in the placebo group. In one good quality RCT 
[21] 16 patients (64%) in the adalimumab group returned to work by six months 
compared with 13 (42%) in the placebo group. 
 
Adverse effects 
There was no significant difference in the number of adverse events between infliximab, 
etanercept or adalimumab and placebo in one non-RCT and five RCTs when these were 
combined in a meta-analysis [21-28], and between epidural injections of etanercept or 
autologous conditioned serum compared with corticosteroid and local anaesthetic 
epidural injections in two RCTs [19,26] (Figure 9). Only one serious adverse effect of 
severe gastrointestinal haemorrhage was reported in a patient receiving adalimumab, 
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which was blamed upon concomitant administration of non-steroidal anti-inflammatory 
medication [21]. 
 
DISCUSSION 
Summary of main findings 
There was insufficient evidence for the efficacy of biological agents targeting TNF 
compared with placebo. Meta-analyses found moderate and statistically significant 
improvements in global effects in the medium term, leg pain intensity in the short term 
and ODI in the medium term when all study types were included. However, there was 
moderate to substantial heterogeneity in the leg pain intensity and ODI results, and the 
meta-analysis results were no longer statistically significant when restricted to RCTs. 
There was a reduction in the need for disc surgery, which was not statistically significant 
and limited evidence for improved employment outcomes. There was no difference in 
the number of adverse effects. Only two studies comparing biological agents with an 
alternative treatment were identified. One was a RCT which, rather than testing a 
medicinal product, tested serum rich in anti-inflammatory cytokines; the other was a 
poor quality cohort study. They provided very limited evidence that a biological agent 
was superior to intra-venous corticosteroids, but not compared with epidural 
corticosteroid.  
 
Strengths and limitations of the study 
One of the strengths of this review was the extensive literature search that was 
undertaken to identify published, unpublished and grey literature. Observational studies 
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and non-randomised trials were included for completeness as some comparisons may 
not have been evaluated by RCTs. Observational studies can have better external 
validity than RCTs [30,31] and provide more generalisable findings, however the RCT is 
widely regarded as the design of choice when assessing the effectiveness of health care 
interventions [32] and we acknowledge the controversy over the inclusion of non-
randomised evidence. In this review, priority was given to RCTs, and the quality of the 
studies noted. We also conducted a sensitivity analysis excluding non-randomised 
evidence.   
 
Poor reporting and variation in the way the data were analysed meant that imputation or 
substitution of missing data was necessary in order for the meta-analyses to be as 
inclusive as possible. Omitting studies with missing SDs may induce bias in the 
summary effect estimate [33], and Furukawa, et al. [17] have shown that it is safe to 
borrow SDs from other studies. The use of imputed SDs was tested in a sensitivity 
analysis. 
 
We identified heterogeneity in many of the meta-analyses performed. It was our 
intention to explore this heterogeneity with meta-regression, where ten or more studies 
were included in the meta-analysis, assessing the effect of study level co-variates such 
as: adequacy of randomisation procedure, allocation concealment, attrition rate and 
blinded outcome assessment. Unfortunately there were insufficient studies to do this. 
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Comparison with existing literature 
This is the first systematic review of biological agents targeting TNF for sciatica. It used 
updated searches from a larger systematic review examining all management strategies 
for sciatica, which included indirect comparisons of different management strategies 
synthesised in a mixed treatment comparison. This mixed treatment comparison (MTC) 
analysis found a significant improvement in leg pain intensity and condition-specific 
outcomes compared with inactive control when all studies were included; but when 
observational studies were excluded these findings were no longer statistically 
significant [12].  
 
This systematic review focused on biological agents targeting TNF. Other cytokines 
have also been implicated in the pathogenesis of sciatica (IL-1, IL-1, IL-6 etc.), but we 
did not identify any other comparator studies of biological agents targeting these 
alternative cytokines in sciatica. Other non-biological pharmacological agents may also 
influence cytokines. There has been one small RCT of one such agent; epidural 
clonidine compared with epidural corticosteroid [34]. The neurophysiology of nerve root 
pain has been complicated further by the discovery of the anti-inflammatory cytokine IL-
10 [35], but agents manipulating this cytokine have yet to be tested in humans. 
 
Implications for future research and clinical practice 
There was insufficient evidence to recommend a change in clinical practice.  There was 
heterogeneity in many of the meta-analyses and the improvements in outcome were 
statistically significant only when non-randomised studies were included. However, 
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these results provide sufficient evidence to suggest that further large RCTs are needed 
to establish the efficacy of biological agents targeting TNF compared with placebo. 
There was a scarcity of RCTs comparing the effectiveness of biological agents with 
other treatments for sciatica; more are needed. Biological agents are expensive but may 
lead to cost savings if a reduction in disc surgery is confirmed; economic evaluations 
alongside RCTs are needed to assess this. 
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APPENDIX MEDLINE (OVID) Search strategy 
 
MEDLINE (OVID) 1950 to June week 1 2008 searched on 16-06-2008 
Search updated on 04-12-2009 and on 01-02-2011 
 
1. Sciatica/ 
2. (ischialg$ or sciatic$).ti,ab.  
3. ((lumb$ or sacra$ or spin$) adj5 radicul$).ti,ab. 
4. ((sciatic nerve or lumbar nerve or spinal nerve or sacral nerve) adj5 (irritation or 
inflammat$ or pain or neuropath$ or dysfunction$ or compressio$ or injur$ or 
traum$)).ti,ab 
5. Intervertebral Disk Displacement/ 
6. ((intervertebral disk or intervertebral disc or lumbar disc or lumbar disk or 
lumbosacral disc or lumbosacral disk or lumbo-sacral disc or lumbo-sacral disk) adj5 
(hernia$ or slip$ or prolapse or degeneration or fusion or sclerosis or rupture or 
distortion or fracture or displacement)).ti,ab. 
7. ((lumbosacral nerve root or lumbo-sacral nerve root or lumbar nerve root) adj5 
(irritat$ or inflammat$ or pain$ or neuropath$ or dysfunction$ or compressio$ or 
injur$ or traum$)).ti,ab. 
8. ((refer$ or radiat$) adj5 (back or leg or foot)).ti,ab. 
9. or/1-8 
10. (treatment$ or therap$ or manag$ or surg$ or modalit$ or intervention$).ti,ab. 
11. Bed rest/ 
12. (bed rest$ or activ$ or exercise$ or education$ or instruction$ or advice$).ti,ab. 
13. Physical Therapy Modalities/ 
14. ((heat or hot or thermal or infra?red or ultrasound or ultrasonic or short-wave or 
physio$ or physical or exercise) adj5 (therap$ or treatm$)).ti,ab. 
15. Transcutaneous Electric Nerve Stimulation/ 
16. (transcutaneous electric nerve stimulation or TENS).ti,ab. 
17. Complementary Therapies/ 
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18. Exp Musculoskeletal Manipulations/ 
19. Exp Acupuncture Therapy/ 
20. ((spina$ or chiropract$ or osteopath$ or physi$ or homeopath$ or acupunctur$ or 
musculo?skeletal or myofunctional) adj5 (massage or manipulat$ or therap$ or 
treatment$)).ti,ab. 
21. Homeopathy/ 
22. homeopathy.ti,ab. 
23. Herbal Medicine/ 
24. herbal medicine.ti,ab. 
25. Orthotic Devices/ 
26. (braces or slings or splints or corset).ti,ab. 
27. Traction/ 
28. traction.ti,ab. 
29. Drug Therapy/ 
30. Exp Analgesics/ 
31. Anti-Inflammatory Agents, Non-Steroidal/ 
32. ((non-steroidal anti inflammatory or non-steroidal anti-inflammatory or non?narcotic 
or narcotic or opioid$ or opiate$) adj5 (drug$ or analges$)).ti,ab.  
33. (paracetamol or acetaminophen).ti,ab. 
34. (ibuprofen or aceclofenac or acemetacin or celecoxib or dexketoprofen or diclofenac 
sodium or etodolac or etoricoxib or fenbufen or fenoprofen or flurbiprofen or 
indometacin or indomethacin or ketoprofen or mefenamic acid or meloxicam or 
nabumetone or naproxen or piroxicam or sulindac or tenoxicam or tiaprofenic acid or 
azapropazone or biarison or acetaminophen or nimesulide or oxyphenbutazone or 
azapropazone or felbinac or alclofenac or nimesulid or etofenama or loxoprofen or 
phenylbutazone or valdecoxib or lornoxicam or etoricoxib).ti,ab. 
35. (buprenorphine or butorphanol or codeine or dextromoramide or 
dextropropoxyphene or dihydromorphine or diphenoxylate or etorphine or fentanyl or 
heroin or hydrocodone or hydromorphone or levorphanol or meperidine or 
meptazinol or methadone or methadyl acetate or morphine or nalbuphine or 
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oxycodone or oxymorphone or pentazocine or phenazocine or phenoperidine or 
pirinitramide or promedol or sufentanil or tilidine or tramadol).ti,ab. 
36. Epidural Analgesia/ 
37. Epidural Injections/ 
38. ((intramuscular or intravenous or peri?neural$ or epidura$ or inject$) adj5 
(cortico?steroid$ or steroid$ or ana?lgesic$ or chymopapain)).ti,ab. 
39. (dexamethasone or hydrocortisone or prednisolone or methylprednisolone or 
prednisone or methylprednisone or triamcinolone).ti,ab. 
40. Orthopedic Procedures/ 
41. Intervertebral Disk Chemolysis/ 
42. ((disc or disk) adj5 (chemolysis or chemonucleolysis)).ti,ab. 
43. Vertebroplasty/ 
44. Diskectomy/ 
45. Neurosurgical Procedures/ 
46. Laminectomy/ 
47. Rhizotomy/ 
48. (discectomy or diskectomy or microdiscectomy or microdiskectomy or rhizotomy or 
sequestrectomy or vertebroplasty or nucleoplasty or laminectomy).ti,ab. 
49. Surgical Decompression/ 
50. surgical decompression.ti,ab. 
51. or/11-50 
52. 9 and 51 
53. limit 52 to human 
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Table 1 Characteristics of studies comparing biological agents with placebo 1 
 2 
Study Participants Intervention Control  
treatment 
Length of  
follow-up 
Outcomes 
Korhonen, 
2004 [27,28] 
Finland, 
Non-RCT 
72 patients with nerve root pain 
confirmed by imaging. Data for 
TNF group only (no data for 
control group);  mean duration 
7.2 weeks; Mean age 39 years; 
80% men  
Intra-venous 
infusion of 
infliximab 3mg/Kg  
Periradicular 
saline injection 
12 months Number of painless patients (>75% decrease 
from baseline leg pain score}; back and leg pain 
intensity (VAS); Oswestry Disability Index; 
number of sick leave days; clinical status, 
adverse effects 
Korhonen, 
2006 [23,24] 
Finland, 
RCT 
41 patients with first or 
recurrent episode of nerve root 
pain confirmed by imaging; 
median duration 61 days; Mean 
age 41 years; 60% men 
Intravenous 
infliximab 5mg/Kg 
Intravenous 
saline injection 
12 months Number of painless patients (>75% decrease 
from baseline leg pain score}; back and leg pain 
intensity (VAS)a,b; Oswestry Disability Indexa,b; 
RAND-36 health questionnaire; number sick 
leave days; number discectomies; clinical 
status, adverse effects 
Karppinen, 
2009 [22] 
Finland, 
RCT 
15 patients with nerve root pain 
confirmed by imaging; disc 
hernaition at L3/4 or L4/5; mean 
duration 58 days; mean age 53 
years; 67% men 
Intravenous 
infliximab 5mg/Kg 
Intravenous 
saline injection 
6 months Back and leg pain intensity (VAS)a,b; Oswestry 
Disability Indexa,b; RAND-36 health 
questionnaire; number sick leave days; number 
discectomies; clinical status, adverse effects 
Cohen, 2009 
[20] 
USA, RCT 
24 patients with nerve root pain 
confirmed by imaging; median 
duration 3-7 months; median 
age 41-46 years; 71% men 
Transforaminal 
epidural injection 
etanercept: 
2mg (Group 1) 
4mg (Group 2) 
6mg (Group 3) 
Transforaminal 
epidural injection 
normal saline 
6 months Number with a positive outcome (>50% 
reduction in leg pain + global perceived effect 
[combination of pain, daily activities improved & 
satisfaction]); back and leg pain intensity 
(numerical rating scale)c; Oswestry Disability 
Indexc; drug consumption;   
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[Results from groups 1-3 combined for the 
meta-analysis] 
Okoro, 2010 
[25] 
UK, RCT 
15 patients with nerve root pain 
confirmed by imaging for at 
least 24 weeks; Mean age not 
stated; 40% men 
Subcutaneous 
injection of 
etanercept 25mg 
Subcutaneous 
injection of 
saline 
3 months Leg pain intensity (VAS)d; Oswestry Disability 
Indexd; modified somatic perception; modified 
Zung depression index; subjective walking 
distance; adverse effects 
Genevay, 
2010 [21] 
Switzerland, 
RCT 
61 patients with first or 
recurrent episode of nerve root 
pain confirmed by imaging; 
mean duration 3.6 weeks; 
Mean age 49 years; 57% men 
Subcutaneous 
injection of 
adalimumab 
40mg x2 
Subcutaneous 
injection of 
saline x2 
6 months Number of responders (>30% improvement 
from baseline leg or back pain score or 
Oswestry Disability Index}; back and leg pain 
intensity (VAS); Oswestry Disability Index, SF-
12v2; drug consumption; number of 
discectomies;  work status; adverse effects 
Cohen, 2012  
[26] 
USA, 
Germany, 
RCT 
84 patients with nerve root pain 
confirmed by imaging; mean 
duration 2.7 months; mean age 
42 years; 70% men 
Transforaminal 
epidural injection 
etanercept 4mg+ 
local anaesthetic 
0.5ml x2 
Transforaminal 
epidural injection 
normal saline+ 
local anaesthetic 
0.5ml x2 
6 months 
(large 
proportion 
left study 
after 1 
month)e 
Positive categorical outcome (>50% decrease in 
leg pain + positive global perceived effect 
obviating the need for further treatment); back 
and leg pain intensity (NRS); Oswestry 
Disability Index; reduction in analgesic 
consumption 
NRS Numeric Rating Scale; RCT Randomised Controlled Trial; SD Standard Deviation; SF-12 Short Form 12; TNF Tumour Necrosis Factor; 1 
VAS Visual Analogue Scale; aSD not reported, imputed from other studies in meta-analyses; bmedians reported; cresult from only a single 2 
patient in control group at 6 month follow-up; dmean leg pain intensity & SDs obtained from authors; eafter 1 month participants who received 3 
no benefit exited the study to pursue other treatments4 
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Table 2 Characteristics of studies comparing biological agents with alternative interventions  1 
 2 
Study Participants Intervention Control treatment Length of 
follow-up 
Outcomes 
Biological agents vs Epidural steroid injection 
Becker et al , 2007 
[19] 
Germany, RCT 
 
84 patients with nerve root pain 
confirmed by imaging for at least 6 
weeks; Mean age 54 years; 62% 
men 
Epidural injection 
of Autologous 
Conditioned 
Serum (Group 1) 
Epidural injection of 
steroid triamcinolone 
5 mg  or 10mg + local 
anaesthetic 1ml 
(Groups 2 & 3) 
22 weeks Overall pain intensity (VAS)a; 
Oswestry Disability Index, adverse 
effects 
[Results from groups 2 & 3 
combined for the forest plot] 
Cohen, 2012  
[26] 
USA, Germany, 
RCT 
84 patients with nerve root pain 
confirmed by imaging; mean 
duration 2.7 months; mean age 42 
years; 70% men 
Transforaminal 
epidural injection 
etanercept 4mg 
Transforaminal 
epidural injection of 
steroid methyl 
prednisolone 60mg + 
local anaesthetic 
0.5ml 
6 months Global perceived effect; back and 
leg pain intensity (NRS); Oswestry 
Disability Index; reduction in 
analgesic consumption 
Biological agents vs Intravenous steroid 
Genevay, 2004 
[29] 
Switzerland, HCS 
20 patients with nerve root pain 
confirmed by imaging; mean 
duration 3.2 weeks; Mean age 47 
years; 50% men 
Subcutaneous 
injection of 
etanercept 25mg 
(anti-TNF alpha) 
x3 
Intravenous injection 
of 
methylprednisolone 
250mg x3 
6 weeks Numbers with a good clinical result 
(leg pain VAS <30 or Oswestry 
Disability Index <20); back and leg 
pain intensity (VAS); Oswestry 
Disability Index; Roland-Morris 
Questionnaire; number of 
discectomies 
HCS Historical Cohort Study; RCT Randomised Controlled Trial; TNF Tumour Necrosis Factor; VAS Visual Analogue Scale; aresults extracted from graphs3 
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Table 3 Quality of included studies 
 
Quality Checklist 
Genevay 
et al, 
2004 
[29] 
Korhonen 
et al, 
2004 
[27,28] 
Korhonen 
et al, 
2006 
[23,24] 
Becker 
et al, 
2007 
[19] 
Karppinen 
et al, 2009  
[22] 
Cohen  
et al, 
2009 
[20] 
Okoro 
et al, 
2010 
[25] 
Genevay 
et al, 
2010 
[21] 
Cohen  
et al, 
2012 
[26] 
External Validity 
         
Are participants 
representative? 
+/- Unclear Unclear +/- Unclear Unclear Unclear +/- +/- 
Percentage who agreed 
to       
participate? 
80-100% Unclear Unclear Unclear Unclear Unclear Unclear <60% 80-100% 
Staff & facilities 
representative? 
+/- +/- +/- +/- + +/- +/- + +/- 
  Rating Moderate Weak Weak Weak Weak Weak Weak Moderate Moderate 
Selection Bias - 
Confounders 
         
Study design? HCS Non-RCT RCT RCT RCT RCT RCT RCT RCT 
Adequate method  
randomisation? 
- - + + + Unclear Unclear + + 
Adequate allocation   
concealment? 
- - +/- +/- Unclear +/- + + + 
Percentage relevant 
prognostic factors? 
60-79% <60% 60-79% <60% <60% 60-79% <60% 80-100% 60-79% 
Similar baseline 
prognostic    
factors? 
+/- Unclear + Unclear Unclear +/- Unclear +/- + 
Recruited from same  
population? 
- - + + + + + + + 
Recruited over same 
time period? 
- - + + + + + + + 
Analysis of co-variance 
or similar? 
- + + + + - - + + 
Co-interventions avoided 
or similar? 
Unclear Unclear Unclear + Unclear + Unclear + + 
  Rating Weak Weak Moderate Moderate Moderate Moderate Moderate Strong Strong 
Detection Bias 
         
Valid outcome 
measurement? 
+ + + + + + + + + 
Reliable outcome  
measurement? 
+ + + + + + + + + 
Similar timing outcome  
assessment? 
+ - + + + + + + + 
Outcome assessors 
blinded? 
- - Unclear + Unclear + + + + 
Data analyst blinded? Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear Unclear 
  Rating Weak Weak Moderate Moderate Moderate Moderate Moderate Moderate Moderate 
Performance Bias 
         
Participants blinded? - - + + Unclear + + + + 
Clinicians blinded? - - Unclear - Unclear + + + + 
Blinding procedure 
tested? 
NA NA Unclear - NA Unclear Unclear Unclear Unclear 
  Rating Weak Weak Moderate Moderate Weak Moderate Moderate Moderate Moderate 
Attrition Bias 
         
Similar characteristics 
drop-outs? 
+ Unclear + + Unclear + + Unclear Unclear 
No differential drop-out? - Unclear + + - + + - + 
Percentage who 
completed the study? 
80-100% Unclear 80-100% 80-100% 80-100% 80-100% 80-100% 80-100% <60% 
Analysis according to 
treatment allocation? 
+ + + + + + + + + 
Analysis included all 
allocated patients? 
+ Unclear + + + + + + - 
  Rating Strong Weak Strong Strong Moderate Strong Strong Moderate Weak 
Overall Rating Weak Weak Moderate Moderate Moderate Moderate Moderate Strong Moderate 
Key: + yes; - no; +/- partial; HCS historical cohort study; RCT randomised controlled trial
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Figure Legends 
 
Figure 1  Systematic review flow chart  
 
Figure 2 Summary of findings of global effects for studies 
comparing biological agents with placebo  
 
Figure 3 Summary of findings of leg pain intensity for studies  
comparing biological agents with placebo 
 
Figure 4 Summary of findings of Oswestry Disability Index for  
studies comparing biological agents with placebo 
 
Figure 5 Summary of findings of global effects for a study 
comparing a biological agent with corticosteroid injection  
 
Figure 6 Summary of findings of overall pain intensity for studies  
comparing biological agents with corticosteroid injection 
 
Figure 7 Summary of findings of Oswestry Disability Index for  
studies comparing biological agents with corticosteroid 
injection 
 
Figure 8 Summary of total numbers of discectomies in studies 
comparing biological agents with placebo 
 
Figure 9 Summary of total numbers of adverse effects for studies 
comparing biological agents with placebo or corticosteroid 
injection 
 
30 
Figure 1  Systematic review flow chart 
References identified by electronic 
searches after removing duplicates 
(n=38443) 
Articles retrieved in full text for 
detailed evaluationand 
assessment for inclusion 
(n=954) 
References obtained from 
other sources (searching 
bibliographies, reference 
list of reviews) 
(n=33) 
References excluded after 
reviewing titles and abstracts 
(n=37522) 
Articles excluded: 
Did not meet inclusion criteria (n=254) 
Unable to retrieve from interlibrary 
loans (n=21) 
Ongoing non-biological studies (n=42) 
Ongoing biological studies (n=4) 
 
Articles concerning sciatica 
(n=552) 
Studies concerning sciatica 
(n=435) 
Biological agent versus 
inactive control included 
in the meta-analyses 
(n=7) 
Excluded studies from review 
Treatments other than biological 
agent (n=426) 
Articles included in the review 
(n=11) 
Studies included in the review 
(n=9) 
Biological agent 
versus corticosteroid 
injection 
(n=3) 
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Figure 2 Summary of findings of global effects for studies comparing biological agents with placebo  
 
Study or Subgroup
1.1.1 Short term follow-up
Korhonen 2004 Non-RCT
Cohen 2009 RCT
Genevay 2010 RCT
Cohen 2012 RCT
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.76; Chi² = 7.96, df = 3 (P = 0.05); I² = 62%
Test for overall effect: Z = 1.23 (P = 0.22)
1.1.2 Medium term follow-up
Korhonen 2004 Non-RCT
Cohen 2009 RCT
Genevay 2010 RCT
Cohen 2012 RCT
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.44; Chi² = 5.63, df = 3 (P = 0.13); I² = 47%
Test for overall effect: Z = 2.03 (P = 0.04)
1.1.3 Long term follow-up
Korhonen 2004 Non-RCT
Korhonen 2006 RCT
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.56; Chi² = 1.98, df = 1 (P = 0.16); I² = 50%
Test for overall effect: Z = 1.10 (P = 0.27)
Events
7
14
22
11
54
8
13
22
10
53
8
14
22
Total
10
18
31
26
85
10
18
31
26
85
10
21
31
Events
17
2
21
15
55
30
1
13
12
56
27
12
39
Total
62
6
30
30
128
62
6
30
30
128
62
19
81
Weight
23.8%
17.1%
29.2%
29.9%
100.0%
21.5%
12.6%
33.1%
32.7%
100.0%
44.4%
55.6%
100.0%
M-H, Random, 95% CI
6.18 [1.43, 26.68]
7.00 [0.92, 53.23]
1.05 [0.35, 3.15]
0.73 [0.25, 2.11]
1.99 [0.66, 5.96]
4.27 [0.84, 21.72]
13.00 [1.20, 140.73]
3.20 [1.11, 9.22]
0.94 [0.32, 2.75]
2.72 [1.04, 7.13]
5.19 [1.02, 26.43]
1.17 [0.32, 4.28]
2.26 [0.53, 9.73]
Year
2004
2009
2010
2012
2004
2009
2010
2012
2004
2006
Biological agent Inactive control Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours placebo Favours biological agent
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Figure 3 Summary of findings of leg pain intensity for studies comparing biological agents with placebo 
Study or Subgroup
1.2.1 Short term follow-up
Korhonen 2004 Non-RCT
Korhonen 2006 RCT
Cohen 2009 RCT
Karppinen 2009 RCT
Okoro 2010 RCT
Genevay 2010 RCT
Cohen 2012 RCT
Subtotal (95% CI)
Heterogeneity: Tau² = 205.11; Chi² = 19.48, df = 6 (P = 0.003); I² = 69%
Test for overall effect: Z = 2.02 (P = 0.04)
1.2.2 Medium term
Korhonen 2004 Non-RCT
Korhonen 2006 RCT
Karppinen 2009 RCT
Genevay 2010 RCT
Okoro 2010 RCT
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.55, df = 4 (P = 0.82); I² = 0%
Test for overall effect: Z = 1.61 (P = 0.11)
1.2.3 Long term follow-up
Korhonen 2004 Non-RCT
Korhonen 2006 RCT
Subtotal (95% CI)
Heterogeneity: Tau² = 190.07; Chi² = 7.25, df = 1 (P = 0.007); I² = 86%
Test for overall effect: Z = 0.02 (P = 0.99)
Mean
18
33
23.3
24
50
31.7
35.6
12
13
17
16.1
48.3
10
23
SD
19
26.1
24.3
26.1
35.1
27.2
31
24
26.5
26.5
24.4
37.6
12
12
Total
10
21
18
7
8
31
26
121
10
21
7
31
8
77
10
21
31
Mean
47
46
65
40
38
29.5
37.8
17
15
28
29.2
42.5
20
12
SD
32
30.2
24
30.2
39.6
25.6
35.7
24
27.9
27.9
33.6
38.6
24
24
Total
62
19
6
8
7
30
30
162
62
19
8
30
7
126
62
19
81
Weight
17.6%
15.9%
13.6%
10.9%
7.8%
18.1%
16.0%
100.0%
27.9%
25.1%
9.4%
32.8%
4.8%
100.0%
51.5%
48.5%
100.0%
IV, Random, 95% CI
-29.00 [-43.22, -14.78]
-13.00 [-30.58, 4.58]
-41.70 [-63.94, -19.46]
-16.00 [-44.49, 12.49]
12.00 [-26.11, 50.11]
2.20 [-11.05, 15.45]
-2.20 [-19.67, 15.27]
-13.63 [-26.84, -0.41]
-5.00 [-21.03, 11.03]
-2.00 [-18.91, 14.91]
-11.00 [-38.55, 16.55]
-13.10 [-27.88, 1.68]
5.80 [-32.88, 44.48]
-6.96 [-15.42, 1.51]
-10.00 [-19.54, -0.46]
11.00 [-0.95, 22.95]
0.18 [-20.39, 20.75]
Year
2004
2006
2009
2009
2010
2010
2012
2004
2006
2009
2010
2010
2004
2006
Biological agent Inactive control Mean Difference Mean Difference
IV, Random, 95% CI
-50 -25 0 25 50
Favours biological agent Favours placebo
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Figure 4 Summary of findings of Oswestry Disability Index for studies comparing biological  
agents with placebo 
Study or Subgroup
1.3.1 Short term follow-up
Korhonen 2004 Non-RCT
Korhonen 2006 RCT
Cohen 2009 RCT
Karppinen 2009 RCT
Genevay 2010 RCT
Okoro 2010 RCT
Cohen 2012 RCT
Subtotal (95% CI)
Heterogeneity: Tau² = 97.68; Chi² = 25.54, df = 6 (P = 0.0003); I² = 77%
Test for overall effect: Z = 1.15 (P = 0.25)
1.3.2 Medium term
Korhonen 2004 Non-RCT
Korhonen 2006 RCT
Karppinen 2009 RCT
Okoro 2010 RCT
Genevay 2010 RCT
Subtotal (95% CI)
Heterogeneity: Tau² = 21.13; Chi² = 7.32, df = 4 (P = 0.12); I² = 45%
Test for overall effect: Z = 2.58 (P = 0.010)
1.3.3 Long term follow-up
Korhonen 2004 Non-RCT
Korhonen 2006 RCT
Subtotal (95% CI)
Heterogeneity: Tau² = 14.92; Chi² = 2.56, df = 1 (P = 0.11); I² = 61%
Test for overall effect: Z = 1.44 (P = 0.15)
Mean
15
35
27.3
44
29.1
46.1
20.13
5
17
26
37
22.1
5
9
SD
9
18.4
20.9
18.4
17.5
15.75
12.34
5
16.6
16.6
16.82
17
5
5
Total
10
21
18
7
31
8
26
121
10
21
7
8
31
77
10
21
31
Mean
30
35
43.3
61
33
31.2
15
13
21
54
35
29
13
10
SD
17
21.3
11.4
21.3
30.3
29.89
10.6
13
16.2
16.2
19.22
22
15
15
Total
62
19
6
8
30
7
30
162
62
19
8
7
30
126
62
19
81
Weight
18.6%
14.9%
14.3%
10.1%
14.9%
8.0%
19.2%
100.0%
37.9%
20.8%
10.7%
9.1%
21.4%
100.0%
57.0%
43.0%
100.0%
IV, Random, 95% CI
-15.00 [-22.00, -8.00]
0.00 [-12.40, 12.40]
-16.00 [-29.28, -2.72]
-17.00 [-37.09, 3.09]
-3.90 [-16.37, 8.57]
14.90 [-9.79, 39.59]
5.13 [-0.94, 11.20]
-5.21 [-14.09, 3.68]
-8.00 [-12.48, -3.52]
-4.00 [-14.17, 6.17]
-28.00 [-44.65, -11.35]
2.00 [-16.40, 20.40]
-6.90 [-16.79, 2.99]
-8.16 [-14.36, -1.96]
-8.00 [-12.85, -3.15]
-1.00 [-8.08, 6.08]
-4.99 [-11.78, 1.80]
Year
2004
2006
2009
2009
2010
2010
2012
2004
2006
2009
2010
2010
2004
2006
Biological agent Control Mean Difference Mean Difference
IV, Random, 95% CI
-20 -10 0 10 20
Favours biological agent Favours placebo
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Figure 5 Summary of findings of overall pain intensity for studies comparing biological agents  
with corticosteroid injection 
 
 
Study or Subgroup
2.1.1 Epidural steroid short term follow-up
Becker 2007 RCT
Cohen 2012 RCT
2.1.2 Epidural steroid medium term follow-up
Becker 2007 RCT
2.1.3 Intravenous steroid short term follow-up
Genevay 2004 HCS
Mean
33
35.6
23.3
12.4
SD
23
31
24.8
13.2
Total
32
26
32
10
Mean
29
25.4
34.7
52.9
SD
24
19.9
28.3
25.1
Total
52
28
52
10
IV, Random, 95% CI
4.00 [-6.30, 14.30]
10.20 [-3.81, 24.21]
-11.40 [-22.93, 0.13]
-40.50 [-58.08, -22.92]
Experimental Control Mean Difference Mean Difference
IV, Random, 95% CI
-50 -25 0 25 50
Favours biological agent Favours steroid injection
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Figure 6 Summary of findings of Oswestry Disability Index for studies comparing biological agents with corticosteroid 
injection 
 
Study or Subgroup
2.2.1 Epidural steroid short term follow-up
Becker 2007 RCT
Cohen 2012 RCT
2.2.2 Epidural steroid medium term follow-up
Becker 2007 RCT
2.2.3 Intravenous steroid short term follow-up
Genevay 2004 HCS
Mean
13.8
20.13
11.7
17.3
SD
9.8
12.35
9.2
13.1
Total
32
26
32
10
Mean
11.6
12.1
11.3
33.4
SD
9.3
8.36
8.7
13
Total
52
28
52
10
IV, Random, 95% CI
2.20 [-2.03, 6.43]
8.03 [2.36, 13.70]
0.40 [-3.57, 4.37]
-16.10 [-27.54, -4.66]
Biological agent Steroid injection Mean Difference Mean Difference
IV, Random, 95% CI
-20 -10 0 10 20
Favours biological agent Favours steroid injection
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Figure 7 Summary of total numbers of discectomies in studies comparing biological agents with  
placebo 
 
 
Study or Subgroup
1.4.1 Biological agent versus inactive control
Korhonen 2004 Non-RCT
Korhonen 2006 RCT
Karppinen 2009 RCT
Genevay 2010 RCT
Okoro 2010 RCT
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 2.76, df = 4 (P = 0.60); I² = 0%
Test for overall effect: Z = 1.61 (P = 0.11)
Events
1
8
1
6
1
17
Total
10
21
7
31
8
77
Events
15
8
1
13
0
37
Total
62
19
8
30
7
126
Weight
12.0%
34.6%
6.3%
42.2%
4.9%
100.0%
M-H, Random, 95% CI
0.35 [0.04, 2.98]
0.85 [0.24, 3.00]
1.17 [0.06, 22.94]
0.31 [0.10, 0.99]
3.00 [0.10, 86.09]
0.54 [0.26, 1.14]
Year
2004
2006
2009
2010
2010
Biological agent Control Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours biological agent Favours placebo
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Figure 8 Summary of total numbers of adverse effects for studies comparing biological agents with placebo  
or corticosteroid injection 
 
Study or Subgroup
1.6.1 Biological agent versus inactive control
Korhonen 2004 Non-RCT
Korhonen 2006 RCT
Cohen 2009 RCT
Karppinen 2009 RCT
Genevay 2010 RCT
Okoro 2010 RCT
Cohen 2012 RCT
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 1.96, df = 3 (P = 0.58); I² = 0%
Test for overall effect: Z = 0.18 (P = 0.86)
1.6.3 Biological agent versus epidural steroid
Becker 2007 RCT
Cohen 2012 RCT
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.75; Chi² = 1.53, df = 1 (P = 0.22); I² = 35%
Test for overall effect: Z = 0.85 (P = 0.39)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 4.22, df = 5 (P = 0.52); I² = 0%
Test for overall effect: Z = 0.73 (P = 0.46)
Test for subgroup differences: Not applicable
Events
0
3
0
1
1
0
5
10
1
5
6
16
Total
10
21
6
7
31
8
26
109
32
26
58
167
Events
0
0
0
2
1
0
6
9
2
1
3
12
Total
62
19
18
8
30
7
30
174
52
28
80
254
Weight
8.3%
10.8%
9.6%
43.3%
71.9%
12.7%
15.4%
28.1%
100.0%
M-H, Random, 95% CI
Not estimable
7.38 [0.36, 152.82]
Not estimable
0.50 [0.04, 7.10]
0.97 [0.06, 16.19]
Not estimable
0.95 [0.25, 3.58]
1.10 [0.39, 3.06]
0.81 [0.07, 9.27]
6.43 [0.70, 59.28]
2.43 [0.32, 18.63]
1.38 [0.58, 3.31]
Year
2004
2006
2009
2009
2010
2010
2012
2007
2012
Biological agent Control Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours biological agent Favours control
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